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Abstract:
Background and objectives: Cardiovascr,rlar diseases (CIVD) are stil1 the leading cause of-
ntortalitv and morbidity' n,orldu'icle. Liver X receptors (t.XRs) and sterol regulatorl' element
hinding proteins (SREBPs) pla,v an irnportant role in lipicl homeostasis. LXRs al'fect SRf,BPs and
increase lipicl sl,nthesis and reverse choiesterol transport (RCl'). MicroRri:\s are endogenous" non-
coding. short RNAs r.vhich play pivotal roles in regulating n:retabolism aud other aspects of cell
biolog.v. MicroRNA-33 down regulates AMPK, ABCIAl and CPI'1 mRNA. On the other hand,
SIRTl afI-ects LXII and SREBP activity through deacet,vlation. In this stuch'r,re evalr,tated effect
of co-administlation o1'miR-33 r.nirnic. inhibitor and LXR activator on AMPK-SIR]'1. LXR-u.
SREBPs and ABCIAi expression iu mice liver.
Materials and methocls: 'l'hirty six mice r.vere divided into six groups (n:6) and the study duratir.rn
u,as 7 da1,.s. Group I received standard chow without any treatment. group II received 30 mg/kg/;t8h
LXR agonist (1'09013i7). group lll received I rng/kg/4Sh "LNA mil{-33 mimic". group IV
receir,,ed 1 m-u/lig/48h ''in vivo LNA anti-miR-33". g1'olrp V received both T0c)01317 and "LNA
n'riR-33 rlimic'". ancl group VI received both 1'090i317 and "in vivo l-NA anti-miR-33". All
treatments rvere aclnrinistratecl througli i.p iniection. After 7 da,vs, uice u'eLe sacritlced and liver
tissues u,ere excised and blood samples were collected. miR-33, Abcal" AN{I'}K. Lxr- o. Sil't1.
Sreb12 anil Srebfic gene expression w'ere quantified by real tirne PCR. and ABCA1" AN'IPK. l-XR-
u. SIRI'I ancl SREBP-2 protein expression by u'esteru blotting. Sertitn lipicl profiie also was
measurecl. Serunr lipicl protile \\.as assa)'ed b1' enzvmatic rnethods.
Results: Our lestrlts showed that T0901317, ar.rti-rniR-3i ancl co-aclntinistration of'T'0901317 and
anti-miR-33 significantll, increased t'IDL-c levels and miR-33 rnimic significarrtll reduced it.
'f0901i17 increasecl SREBP-2 ancl miR-33 levels but co-adtninistration of'T0901317 and anti-
miR-jireclucecl srebD and miR-33 levels. AMPK u,as reduced b1' T0c)tJ 13 1 7 insignificantl-v. Anti-
ntil{-33 11c1 r.r-riR-i3 ntimic signiticarr-rtly increased and decreased ANII']K expressiot.t respectivell'.
Sir.t1 gene ancl protein erpression rernained unchanged in all six grollps. Our resr-tlts showed tirat
I-XR activation canse LXR-g and ABCIAl eler.'ation and miR-33 inhibition attenrtates T0901317
etfect on LXR-cr explession. '10901317 and conrbination o1'T0901317 and miR-33 rnin-ric
signiticantll, increased and anti-miR-33 reduced SREBP-1c gene expressiot.t. '10901317 and
cornbination of T0901317 and rniR-33 min'ric significantly'it.rcreased'i'C levels.
i rircussion: In spite o1'progress in drug discovery for atherosclerosis and tnetabolic diseases, these
- 
:,.rrders are not fully controlled. It seem that there is a s-vnergistic efl-ect betu'een T0901317 and
'.i-nriR-33 rvhich reduce serlrlrr TG lerrels. and also reduce intracellular sterol levels and iucrease
- .,.',iesterol transport to hepatocl,tes, theretbre this can be considered as a therapetttic alternative in
-rerosclerosis and cardiovascular diseases.





+"U Olr-1" ;l glso a.,,W )yo
6L;S.S,r; :,+ , ---
o61,:,jlc.Ja^53 ill.s 
-
.K;1, ,=lii;r or5i;1, d!,#X d..:r (Ph.D) 6,a4-;,g;t: 6j,r:;rr ,rljSAti <lt.qr 5t5T M.,L; ,rL-1. tr:- *
AMPK-SIRT1 sL, fk 
--.,1: SREBP23 SIRTl ,AMPK dr* / miR-3 3 t4fuI , ,-*-Si c.,ljl ".rlr;c c*j ,itf --<, .
:j'-tar1 ,-rl13b ol9 ;ra, 6llol .;j,)> t tliti I11.l;," $ )s: g"a 1:l'i-L-2: " ut- -
,*ri; .rr ...-.1../:.6.u1.1/ *.... .,,- e ....-....,,.*J.k..,.....,.. c?rJ Lr i-ta, cr; { ,r1L-;rl ,r e *-r.5 ---
,rSol9;la eU f eU
.gur,*. dl.ir"Yr;So 6t9T -U.a
C)ls O*- 15o.gLii u,l;.7
Qblc) ;rfelo o[a *ac:6
r.-f A.r-rl l"r.DG r:9o.gt5T.*,t"q
Ot{ii,..-*.)G.ra>l .,:fc Al3l Vt^a
(,rl-l"r) 6lr9lc otp ,*:6
("f.rt-) 6!9lc o[o q*ic] s
.5;i.ir-,r*;.rs> J5o dL5i HU"
(.f_rl-) 6lr9lc ol.-o q.icl s
,rr-9ar oLslt ;5o 6t5T ./ti+ \
.gog.f3J 6sY;5c rt E t|5:*
.l--tt diY-.4r!, oJlt^il o9i
.&,i .f
:-
(tr)
